Loading...

Daiichi Sankyo Company, Limited

DSNKYPNK
Healthcare
Drug Manufacturers - General
$24.10
$-0.68(-2.74%)

Daiichi Sankyo Company, Limited (DSNKY) Financial Performance & Income Statement Overview

Analyze Daiichi Sankyo Company, Limited (DSNKY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
17.77%
17.77%
Operating Income Growth
43.34%
43.34%
Net Income Growth
47.34%
47.34%
Operating Cash Flow Growth
-91.02%
91.02%
Operating Margin
16.12%
16.12%
Gross Margin
77.96%
77.96%
Net Profit Margin
15.68%
15.68%
ROE
17.95%
17.95%
ROIC
11.25%
11.25%

Daiichi Sankyo Company, Limited (DSNKY) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Daiichi Sankyo Company, Limited DSNKY financial performance.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$518.69B$484.84B$446.55B$436.18B
Cost of Revenue$94.34B$128.38B$98.03B$95.05B
Gross Profit$424.35B$356.46B$348.52B$341.13B
Gross Profit Ratio$0.82$0.74$0.78$0.78
R&D Expenses$133.32B$109.32B$92.61B$100.71B
SG&A Expenses$208.21B$185.63B$162.24B$175.12B
Operating Expenses$341.53B$295.05B$254.85B$248.15B
Total Costs & Expenses$435.87B$423.43B$380.56B$343.20B
Interest Income$2.87B$13.46B$0.00$19.13B
Interest Expense$7.08B-$7.45B$11.62B$1.97B
Depreciation & Amortization$17.98B$17.37B$16.68B$16.61B
EBITDA$104.47B$78.78B$110.60B$109.59B
EBITDA Ratio$0.20$0.16$0.25$0.25
Operating Income$82.82B$61.41B$93.67B$92.98B
Operating Income Ratio$0.16$0.13$0.21$0.21
Other Income/Expenses (Net)-$3.42B$21.003B-$11.36B$17.22B
Income Before Tax$79.41B$82.41B$82.31B$110.20B
Income Before Tax Ratio$0.15$0.17$0.18$0.25
Income Tax Expense-$6.52B$20.49B$21.09B$24.82B
Net Income$87.15B$61.93B$61.29B$85.38B
Net Income Ratio$0.17$0.13$0.14$0.20
EPS$46.31$32.75$31.97$44.60
Diluted EPS$46.31$32.75$31.94$44.57
Weighted Avg Shares Outstanding$1.88B$1.89B$1.92B$1.91B
Weighted Avg Shares Outstanding (Diluted)$1.88B$1.89B$1.92B$1.92B

Over the last four quarters, Daiichi Sankyo Company, Limited's revenue moved from $436.18B in Q1 2024 to $518.69B in Q4 2024. Operating income in Q4 2024 was $82.82B, with a strong operating margin of 16%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Daiichi Sankyo Company, Limited remained robust at $104.47B, reflecting operational efficiency. Net income rose to $87.15B, with an EPS of $46.31. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;